BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers BASKING RIDGE, N.J., June 13, 2024 ...
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies...
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 ...
Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024 Projected available cash to fund planned operations into early 2026 covering all studies through data Conference call...
BASKING RIDGE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies...
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies...
BASKING RIDGE, N.J. and JINAN, China, April 23, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing...
BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (œLisata or the œCompany), a clinical-stage pharmaceutical company developing innovative therapies...
BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies...